Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

- Unblinded Data Established a…

Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer

NEW YORK, Dec. 9, 2021…

Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis

NEW YORK, Nov. 18, 2021…

Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity

– Fully Enrolled Phase 2…

Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis

  – Top-Line Data Expected…

Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

NEW YORK, Oct. 14, 2021…

Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis

NEW YORK, Sept. 30, 2021…

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

Immunic and the University Medical…

Immunic, Inc. Announces Closing of $45.0 Million Public Offering

Immunic, Inc. Announces Closing of…

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

Immunic, Inc. Announces FDA Clearance…